Abstract
An estimated 350 million people are chronically infected with hepatitis B virus (HBV), and over one million people die each year due to HBV-associated liver diseases, such as cirrhosis and liver cancer. Current therapeutics for chronic HBV infection are limited to nucleos(t)ide analogs and interferon. These anti-HBV drugs in general reduce viral load and improve the long-term outcome of infection but very rarely lead to a cure. Thus, new therapies for chronic HBV infection need to be developed by utilizing liver cell lines and primary cultures and small laboratory animals capable of replicating HBV or surrogate hepadnaviruses for antiviral testing. Natural infection with woodchuck hepatitis virus (WHV), a hepadnavirus closely related to HBV, occurs in woodchucks. Chronic WHV infection has been established over decades as a suitable model for evaluating direct-acting antivirals as well as vaccines, vaccine adjuvants, and immunotherapeutics because animals are fully immunocompetent. Before HBV-specific compounds are applied to woodchucks, they are usually tested in primary woodchuck hepatocytes (PWHs) replicating WHV at high levels for confirming drug specificity against viral or host targets. Here we describe a protocol for the isolation of PWHs from liver of WHV-infected woodchucks, maintenance in culture, and use in assays for determining antiviral efficacy, safety, and associated host innate immune response of new experimental drugs. Exemplary assays were performed with the nucleoside analog, lamivudine, and the immunomodulator, interferon-alpha.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11(2):97–107
Feitelson MA, Larkin JD (2001) New animal models of hepatitis B and C. ILAR J 42(2):127–138
Fletcher SP, Chin DJ, Cheng DT, Ravindran P, Bitter H, Gruenbaum L, Cote PJ, Ma H, Klumpp K, Menne S (2013) Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B. Hepatology 57(1):13–22
Fletcher SP, Chin DJ, Ji Y, Iniguez AL, Taillon B, Swinney DC, Ravindran P, Cheng DT, Bitter H, Lopatin U, Ma H, Klumpp K, Menne S (2012) Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology 56(3):820–830
Menne S, Cote PJ (2007) The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol 13(1):104–124
Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS (1997) Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 71(12):9392–9399
Jacob JR, Liu RH, Roneker CA, de Noronha F, Hotchkiss JH, Tennant BC (1994) Characterization and immortalization of woodchuck hepatocytes isolated from normal and hepadnavirus-infected woodchucks (Marmota monax). Exp Cell Res 212(1):42–48
Kwon H, Lok AS (2011) Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 8(5):275–284
Menne S, Butler SD, George AL, Tochkov IA, Zhu Y, Xiong S, Gerin JL, Cote PJ, Tennant BC (2008) Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother 52(10):3617–3632
Korba BE, Cote P, Hornbuckle W, Schinazi R, Gangemi JD, Tennant BC, Gerin JL (2000) Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks. Antivir Ther 5(2):95–104
Schoggins JW, Rice CM (2011) Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 1(6):519–525
Swiecki M, Colonna M (2011) Type I interferons: diversity of sources, production pathways and effects on immune responses. Curr Opin Virol 1(6):463–475
Berraondo P, Di Scala M, Korolowicz K, Thampi LM, Otano I, Suarez L, Fioravanti J, Aranda F, Ardaiz N, Yang J, Kallakury BV, Tucker RD, Vasquez M, Menne S, Prieto J, Gonzalez-Aseguinolaza G (2015) Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. J Hepatol 63(2):329–336
Fiedler M, Rodicker F, Salucci V, Lu M, Aurisicchio L, Dahmen U, Jun L, Dirsch O, Putzer BM, Palombo F, Roggendorf M (2004) Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo. J Virol 78(18):10111–10121
Salucci V, Lu M, Aurisicchio L, La Monica N, Roggendorf M, Palombo F (2002) Expression of a new woodchuck IFN-alpha gene by a helper-dependent adenoviral vector in woodchuck hepatitis virus-infected primary hepatocytes. J Interferon Cytokine Res 22(10):1027–1034
Fletcher SP, Chin DJ, Gruenbaum L, Bitter H, Rasmussen E, Ravindran P, Swinney DC, Birzele F, Schmucki R, Lorenz SH, Kopetzki E, Carter J, Triyatni M, Thampi LM, Yang J, AlDeghaither D, Murredu MG, Cote P, Menne S (2015) Intrahepatic transcriptional signature associated with response to interferon-alpha treatment in the woodchuck model of chronic hepatitis B. PLoS Pathog 11(9):e1005103
Freitas N, Salisse J, Cunha C, Toshkov I, Menne S, Gudima SO (2012) Hepatitis delta virus infects the cells of hepadnavirus-induced hepatocellular carcinoma in woodchucks. Hepatology 56(1):76–85
Theze N, Gripon P, Fourel I, Hantz O, Trepo C, Guguen-Guillouzo C (1987) Maintenance of woodchuck hepatitis virus activity in woodchuck hepatocyte primary culture. J Gen Virol 68(Pt 4):1029–1039
Menne S, Tumas DB, Liu KH, Thampi L, AlDeghaither D, Baldwin BH, Bellezza CA, Cote PJ, Zheng J, Halcomb R, Fosdick A, Fletcher SP, Daffis S, Li L, Yue P, Wolfgang GH, Tennant BC (2015) Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol 62(6):1237–1245
Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264(5164):1415–1421
Acknowledgment
M.G.M. was supported by a research grant from Hoffmann-La Roche (Basel, Switzerland). S.O.G. and S.M. were supported by NIH grant R01CA166213.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Murreddu, M.G., Suresh, M., Gudima, S.O., Menne, S. (2017). Measurement of Antiviral Effect and Innate Immune Response During Treatment of Primary Woodchuck Hepatocytes. In: Guo, H., Cuconati, A. (eds) Hepatitis B Virus. Methods in Molecular Biology, vol 1540. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6700-1_24
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6700-1_24
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6698-1
Online ISBN: 978-1-4939-6700-1
eBook Packages: Springer Protocols